CPT® 55700 Is Gone. Here’s How to Protect Your Practice’s Revenue.
The new 2026 prostate biopsy CPT® codes are here and practices that haven’t adopted MRI-fusion biopsy technology are already at risk of revenue loss. Discover how Navigo 4D Fusion Navigation from UC-Care keeps your urology practice aligned, reimbursed, and ahead.
CPT® 55700 Deleted. New Prostate Biopsy CPT® Codes 2026 Are Now in Effect.
As of January 1, 2026, CPT® code 55700 has been officially eliminated. The AMA has replaced it with nine new prostate biopsy CPT® codes that specifically prioritize MRI-targeted fusion biopsy procedures across all care settings — physician office, ASC, and hospital.
​
What this means for your practice:
-
You can no longer bill under CPT® 55700 — effective immediately
-
Practices without MRI-fusion biopsy technology face direct reimbursement risk under the new CMS prostate biopsy reimbursement structure
-
The new codes favor MRI-fusion guided procedures — practices that adopt now protect revenue and gain a competitive edge
Navigo 4D Fusion Navigation System is fully aligned with the new 2026 prostate biopsy CPT® codes — with the lowest upfront cost of any full-featured MRI fusion biopsy system available. Find out exactly what reimbursement looks like for your site of care.​
In-House Prostate Fusion: Capture the Best of Both Worlds With Accurate and Cost-Effective MRI Fusion-Guided Prostate Biopsy
MRI-US fusion is clinically proven to detect higher rates of high-grade prostate cancer compared to traditional ultrasound-guided biopsies. With the new 2026 prostate biopsy CPT® codes now rewarding MRI-fusion procedures, bringing fusion biopsy in-house isn’t just a clinical upgrade — it’s a financial imperative.
While the benefits of in-house MRI fusion biopsy are widely recognized, many urology practices have been held back by the costs and complexity of existing systems. That’s exactly where Navigo 4D Fusion Navigation comes in.
​​
Navigo was specifically designed to remove the barriers to in-office fusion biopsy by delivering the ultimate combination of ease of use, scheduling efficiency, and affordability — at any site of care.
Schedule a call to find out how Navigo can:
Schedule a Navigo Discovery Call
Enhance biopsy precision by compensating for patient movement in real time
Protect your bottom line with low upfront costs, flexible payment options, and a pay-per-procedure program aligned with new CPT® reimbursement rates
Streamline your MRI fusion prostate biopsy workflow by eliminating manual repositioning, re-registration and biopsy marking
Expand access by bringing fusion biopsies in-house — physician office, ASC, or hospital
UC-Care’s Pay-Per-Procedure Model
With Navigo, bringing MRI-guided biopsies in-house is not only feasible, it’s financially beneficial through UC-Care’s pay-per-procedure program. With the right setup, practices can achieve full ROI within the first year, driven by higher reimbursement, increased efficiency, and more treatment procedures enabled by improved detection of high-grade disease.
Prostate Fusion Navigation Systems: A Comparison Guide
With new prostate biopsy CPT® codes now replacing CPT® 55700, selecting the right MRI fusion biopsy system has direct implications for your practice’s reimbursement, workflow, and long-term revenue. Evaluate Navigo 4D against other available systems across the factors that matter most in 2026.
Evaluating Alternatives to UroNav, Koelis Trinity, or Another Fusion Biopsy System?
With CPT® 55700 eliminated and the new 2026 prostate biopsy CPT® codes now rewarding MRI-fusion guided procedures, now is the time to make sure your fusion biopsy system is working for your practice — clinically and financially.
Schedule a demo to see first-hand how Navigo 4D stacks up: how it performs, what it costs, and how it aligns with the new CMS prostate biopsy reimbursement structure to maximize your practice’s revenue from Day 1.
.webp)
UROLOGY WHITE PAPER
Why Bringing Prostate MRI-US Fusion Procedures In-House Makes Clinical and Business Sense
Download this new white paper to learn how moving fusion biopsies in-house can:
Significantly increase prostate cancer detection rates
Simplify patient scheduling and increase practice efficiency
Build new revenue streams to optimize practice profitability
